Show simple item record

dc.contributor.authorMitchell, P
dc.contributor.authorThatcher, Nick
dc.contributor.authorSocinski, M
dc.contributor.authorWasilewska-Tesluk, E
dc.contributor.authorHorwood, K
dc.contributor.authorSzczesna, A
dc.contributor.authorMartín, C
dc.contributor.authorRagulin, Y
dc.contributor.authorZukin, M
dc.contributor.authorHelwig, C
dc.contributor.authorFalk, M
dc.contributor.authorButts, C
dc.contributor.authorShepherd, F
dc.date.accessioned2015-03-19T11:29:04Zen
dc.date.available2015-03-19T11:29:04Zen
dc.date.issued2015-02-26en
dc.identifier.citationTecemotide in unresectable stage III non-small cell lung cancer in the phase III START study: Updated overall survival and biomarker analyses. 2015: Ann Oncolen
dc.identifier.issn1569-8041en
dc.identifier.pmid25722382en
dc.identifier.doi10.1093/annonc/mdv104en
dc.identifier.urihttp://hdl.handle.net/10541/346885en
dc.description.abstractTecemotide is a MUC1-antigen-specific cancer immunotherapy. The phase III START study did not meet its primary endpoint but reported notable survival benefit with tecemotide versus placebo in an exploratory analysis of the predefined patient subgroup treated with concurrent chemoradiotherapy. Here, we attempted to gain further insight into the effects of tecemotide in START.
dc.languageENGen
dc.language.isoenen
dc.rightsArchived with thanks to Annals of oncology : official journal of the European Society for Medical Oncology / ESMOen
dc.titleTecemotide in unresectable stage III non-small cell lung cancer in the phase III START study: Updated overall survival and biomarker analyses.en
dc.typeArticleen
dc.contributor.departmentOlivia Newton-John Cancer and Wellness Centre, Austin Hospital, Melbourne, VIC, Australiaen
dc.identifier.journalAnnals of Oncologyen
html.description.abstractTecemotide is a MUC1-antigen-specific cancer immunotherapy. The phase III START study did not meet its primary endpoint but reported notable survival benefit with tecemotide versus placebo in an exploratory analysis of the predefined patient subgroup treated with concurrent chemoradiotherapy. Here, we attempted to gain further insight into the effects of tecemotide in START.


This item appears in the following Collection(s)

Show simple item record